Yann I. P.
- Country
- Spain
- Department
- Oncología Médica
Research Overview
- Palazestrant and Ribociclib versus Letrozole and Ribociclib for First-line Treatment of ER+/HER2- Advanced Breast Cancer
- Phase III Trial of BNT327 plus Combination Chemotherapy versus Placebo plus Chemotherapy in Patients with Previously Untreated Metastatic or Locally Recurrent Triple-Negative Breast Cancer
- Phase 3 Randomized Study of Gedatolisib Combination Therapy versus Standard Endocrine Therapy in HR‑Positive, HER2‑Negative Advanced Breast Cancer Post‑CDK4/6 Inhibitor
Data & Insights
Has run more than one trial at 431 of 756 partner sites.
Specializations
Breast Cancer Therapeutics
The investigator specializes in treating various forms of early-stage breast cancer, with particular emphasis on hormone receptor-positive and HER2-positive breast cancers.
- Endocrine Therapy Approaches
- HER2-Targeted Treatments
- Neoadjuvant Therapy Strategies
Their research encompasses innovative therapeutic approaches for both node-positive and high-risk breast cancer cases.
Immunotherapy Research
The investigator focuses on advancing immunotherapeutic treatments in breast cancer, particularly studying the effectiveness of atezolizumab in combination with traditional chemotherapy regimens.
- Triple-Negative Breast Cancer Treatment
- Combination Therapy Approaches
- Novel Immunotherapy Applications
Their work includes evaluation of treatment responses in various breast cancer subtypes.
Precision Medicine
The investigator explores targeted therapeutic approaches using biomarker analysis, including ctDNA monitoring for early detection of disease progression.
- Molecular Targeting Strategies
- Biomarker-Driven Treatments
- Personalized Treatment Protocols
Their research incorporates innovative methods for treatment optimization in breast cancer therapy.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.